Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%

Phase 2Completed
0 watching 0 views this week Active
52
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dermatitis, Atopic

Conditions

Dermatitis, Atopic

Trial Timeline

Apr 1, 2003 → Dec 1, 2004

About Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%

Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03% is a phase 2 stage product being developed by Astellas Pharma for Dermatitis, Atopic. The current trial status is completed. This product is registered under clinical trial identifier NCT00535691. Target conditions include Dermatitis, Atopic.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00535691Phase 2Completed

Competing Products

20 competing products in Dermatitis, Atopic

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
77
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
77
LebrikizumabEli LillyApproved
85
LebrikizumabEli LillyPhase 3
77
Lebrikizumab + PlaceboEli LillyPhase 3
77
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
25
LebrikizumabEli LillyPhase 3
77
ASN008Formation BioPhase 2
44
ENS-002Concerto BiosciencesPhase 1
25
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
52
DS-2741a + PlaceboDaiichi SankyoPhase 1
33
SUN13834 + PlaceboDaiichi SankyoPhase 2
52
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
52
tacrolimus ointmentAstellas PharmaPhase 3
77
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
85
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
85
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaApproved
85
Tacrolimus Ointment 0.1%Astellas PharmaPhase 2
52
tacrolimus ointmentAstellas PharmaPhase 3
77